We are a leader in medical research and development for healthy tissue regeneration.

Our proprietary platform regulates Wnt/Beta-Catenin as well as modulates disease and tissue specific molecular pathways. We develop therapeutics to address a range of degenerative diseases, immune conditions and regenerative medicines.

Our addressable market exceeds $500 Billion with rapid time to commercialization by following a non-drug regulatory pathway.